Despite winning an alopecia areata approval for its drug Leqselvi in July, Sun Pharma will have to wait a while longer to ...

Sun Pharma is set to announce its Q2 FY25 results, with revenue growth expected to be driven by domestic business and higher ...

Pharma major Sun Pharma is expected to report healthy revenue growth during the second quarter, driven by its domestic ...

How will India’s leading drugmaker handle legal setbacks, volatile market trends, and competition in generics and specialty products?

Brand-heavy companies such as Mankind Pharma, Sun Pharma, Torrent Pharmaceuticals and Eris Lifesciences are expected to ...

2024 Indian drugmaker Sun Pharma posts Q1 profit beat on strong local sales August 1, 2024 Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news ...

Sun Pharmaceutical Industries reported a 28% rise in net profit, reaching Rs 3,040 crore for the September quarter, driven by ...

Thirty out of the 41 analysts tracking the company have a 'buy' rating on the stock, seven suggest a 'hold' and four have a ...

Shares of Sun Pharmaceutical Industries Ltd. 524715 inched down 0.31% to 1,803.25 Indian rupees Tuesday, on what proved to be ...

India's Sun Pharmaceutical has signed an agreement ... that will be paid to Concert shareholders if deuroxilitinib meets certain sales targets within a set time limit. Alopecia areata is an ...

This segment, which Sun Pharma calls 'high growth', contributed to more than 18% of its total sales in fiscal year 2024. Sun Pharma, which also makes copycat generic drugs and branded versions ...